Partial Validation of Ultra Performance Liquid Chromatography Method for Quantification of Isoniazid-Pyrazinamide in Human Samples

Vycke Yunivita (Universitas Padjadjaran)
Triana Nurul Meirina (Pharmacokinetic Laboratory, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia)
Atu Purnama Dewi (Pharmacokinetic Laboratory, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia)
Harold Eka Atmaja (Pharmacokinetic Laboratory, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia)
Rovina Ruslami (Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran)

The Journal of Pure and Applied Chemistry Research
Vol 10, No 3 (2021): Edition September-December 2021

Isoniazid (INH) and pyrazinamide (PZA) are first-line drugs in the treatment of meningitis of tuberculosis, in addition to rifampicin. The use of these drugs will determine the success of therapy to kill Mycobacterium tuberculosis in brain tissue that is difficult to penetrate by other drugs. Therefore, it is necessary to conduct research and monitor the use of this drug in plasma and cerebrospinal fluid (CSF) patients with TBM. This study aimed to determine the method of analysis of INH and PZA using Ultra Performance Liquid Chromatography Ultra Violet (UPLC-UV). The samples were taken from TBM patients who taken INH-PZA and others besides TBM patients who did not take INH-PZA. The analytic method carried out includes a comparison of the results of the analysis method for measuring levels of standard INH-PZA and INH-PZA in plasma and CSF samples. Analysis of INH-PZA in plasma and CSF can be performed using UPLC with UV detector, at least 100 uL plasma or CSF samples volume, with reproducible and accurate results.